You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Dabrafenib

Showing 1 - 25 of 171
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Colorectal Cancer Trial in Hangzhou (Cetuximab Dabrafenib Tislelizumab)

Not yet recruiting
  • Advanced Colorectal Cancer
  • Cetuximab Dabrafenib Tislelizumab
  • Hangzhou, Zhejing, China
    Zhejiang Cancer Institute & Hospital
Jul 19, 2023

Cancer Trial (Dabrafenib, Trametinib)

Not yet recruiting
  • Cancer
  • (no location specified)
May 25, 2023

Aspirin in Combination With Trametinib and Dabrafenib

Not yet recruiting
  • NSCLC
  • +4 more
  • Combind asprin with Trametinib and Dabrafenib
  • (no location specified)
Aug 4, 2023

Healthcare Resource Utilization and Costs in Metastatic Melanoma

Terminated
  • Metastatic Melanoma
    • East Hanover, New Jersey
      Novartis Investigational Site
    Apr 27, 2023

    Melanoma Trial in Norway (BGB324+pembrolizumab, BGB324+dabrafenib and trametinib, pembrolizumab)

    Active, not recruiting
    • Melanoma
    • Bergen, Norway
    • +4 more
    Aug 24, 2022

    Dabrafenib Plus Trametinib In Rare BRAF V600E Mutation-Positive

    Not yet recruiting
    • Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors
    • Non-investigational
    • (no location specified)
    May 11, 2023

    BRAF NP_004324.2:p.V600E, BRAF V600K Mutation Present, Thyroid Gland Anaplastic Carcinoma Trial in Duarte, Columbus (Dabrafenib,

    Recruiting
    • BRAF NP_004324.2:p.V600E
    • +2 more
    • Dabrafenib
    • +2 more
    • Duarte, California
    • +1 more
    Jan 19, 2023

    Metastatic Melanoma, BRAF Gene Mutation Trial in Lexington (Nilotinib 100mg, Nilotinib 200mg, Nilotinib 300mg)

    Recruiting
    • Metastatic Melanoma
    • BRAF Gene Mutation
    • Nilotinib 100mg
    • +5 more
    • Lexington, Kentucky
      Markey Cancer Center
    Jul 22, 2022

    Associated Factors, and Clinical Outcomes of Prescribing

    Completed
    • BRAF v600 Mutated Metastatic Melanoma
      • East Hanover, New Jersey
        Novartis Pharmaceuticals
      Mar 28, 2023

      Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Tumor in the Brain, Metastatic Malignant Tumor in the CNS

      Recruiting
      • Clinical Stage IV Cutaneous Melanoma AJCC v8
      • +3 more
      • Dabrafenib
      • MEK-1/MEKK-1 Inhibitor E6201
      • Scottsdale, Arizona
      • +2 more
      Jan 4, 2023

      Metastatic Colorectal Cancer Trial in Boston (Dabrafenib, Trametinib, PDR001)

      Recruiting
      • Metastatic Colorectal Cancer
      • Dabrafenib
      • +2 more
      • Boston, Massachusetts
      • +1 more
      Jun 24, 2022

      Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID

      Active, not recruiting
      • Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
      • +2 more
      • Dabrafenib
      • +3 more
      • Houston, Texas
        M D Anderson Cancer Center
      Aug 9, 2022

      Malignant Melanoma, Brain Metastases Trial in Tucson (E6201, E6201 plus dabrafenib)

      Terminated
      Has Results
      • Malignant Melanoma
      • Brain Metastases
      • Tucson, Arizona
        University of Arizona Cancer Center
      Mar 5, 2022

      Tafinlar® + Mekinist® (Dabrafenib + Trametinib)

      Recruiting
      • Malignant Melanoma
      • dabrafenib + trametinib
      • Coimbra, Center, Portugal
      • +5 more
      Jun 9, 2022

      Thyroid Gland Anaplastic Carcinoma, Thyroid Gland Squamous Cell Carcinoma Trial in Houston, Salt Lake City (procedure, drug,

      Recruiting
      • Thyroid Gland Anaplastic Carcinoma
      • Thyroid Gland Squamous Cell Carcinoma
      • Conventional Surgery
      • +5 more
      • Stanford, California
      • +5 more
      Jan 26, 2023

      BRAF V600-mutated Lung Carcinoma Treated With Combination of

      Completed
      • Non Small Cell Lung Cancer
      • BRAF V600 Mutation
        • Créteil, France
        • +1 more
        Jun 29, 2022

        Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma Trial in United States (Dabrafenib Mesylate, Tazemetostat

        Recruiting
        • Clinical Stage IV Cutaneous Melanoma AJCC v8
        • Metastatic Melanoma
        • Dabrafenib Mesylate
        • +2 more
        • Atlanta, Georgia
        • +6 more
        Nov 30, 2022

        Melanoma, Adjuvant Trial (Dabrafenib and Trametinib, Dabrafenib, Trametinib)

        Available
        • Melanoma
        • Adjuvant
        • Dabrafenib and Trametinib
        • +2 more
        • (no location specified)
        Mar 1, 2022

        Metastatic Malignant Tumor in the Brain, Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7 Trial in Houston (drug,

        Active, not recruiting
        • Metastatic Malignant Neoplasm in the Brain
        • +7 more
        • Houston, Texas
          M D Anderson Cancer Center
        Jun 15, 2022

        Melanoma Trial in Sydney, Wollstonecraft, Melbourne (Dabrafenib, Trametinib, Pembrolizumab)

        Active, not recruiting
        • Melanoma
        • Dabrafenib
        • +2 more
        • Sydney, New South Wales, Australia
        • +2 more
        Apr 4, 2022

        Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 Trial

        Active, not recruiting
        • Clinical Stage IV Cutaneous Melanoma AJCC v8
        • +4 more
        • Dabrafenib Mesylate
        • +3 more
        • Philadelphia, Pennsylvania
          Perelman Center for Advanced Medicine
        Dec 29, 2021

        BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Malignant Solid Tumor Trial in Boston (Dabrafenib,

        Active, not recruiting
        • BRAF V600E Mutation Present
        • +9 more
        • Dabrafenib
        • +4 more
        • Boston, Massachusetts
        • +1 more
        Jun 28, 2022

        Anaplastic Thyroid Cancer, Thyroid Cancer, BRAF Gene Mutation Trial in United States (Dabrafenib, Trametinib)

        Recruiting
        • Anaplastic Thyroid Cancer
        • +3 more
        • Basking Ridge, New Jersey
        • +6 more
        Jul 1, 2022

        NSCLC Trial in China (Dabrafenib, Trametinib)

        Recruiting
        • Carcinoma, Non-Small-Cell Lung
        • Harbin, Heilongjiang, China
        • +9 more
        Jun 13, 2022

        Dabrafenib in Combination With Trametinib as Adjuvant Treatment

        Recruiting
        • Melanoma
        • Zhengzhou, Henan, China
        • +6 more
        Mar 17, 2022